Ελληνική Εταιρεία Καρδιαγγειακής Προστασίας

20 Aug Η ΑΞΙΟΛΟΓΗΣΗ ΤΗΣ 24-ΩΡΗΣ ΔΙΑΚΥΜΑΝΣΗΣ ΤΗΣ ΑΡΤΗΡΙΑΚΗΣ ΠΙΕΣΗΣ

Posted at 10:29h in Μελέτες by paroukatos

ΑΝΔΡΕΑΣ ΠΙΤΤΑΡΑΣ MD Ο Κιρκάδειος τύπος διακύμανσης της Αρτηριακής πίεσης Κλινικές και θεραπευτικές επιπτώσεις Blood pressure varies widely over 24 hours, and this may contribute to the fact that acute cardiovascular events peak in the morning hours. Reducing morning BP may prevent these occurrences, and so identifying...

20 Aug CHARM

Posted at 10:28h in Μελέτες by paroukatos

Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial McMurray JJV, Young JB, Dunlap ME, Granger CB, Hainer J, Michelson EL et al on behalf of the...

20 Aug Clinical Significance of an Exaggerated Blood Pressure Response During Exercise

Posted at 10:28h in Μελέτες by paroukatos

ANDREAS PITTARAS MD Κατεβάστε την πλήρη παρουσίαση σε μορφή διαφανειών Powerpoint....

20 Aug The Study of Trandolapril-verapamil And insulin Resistance

Posted at 10:27h in Μελέτες by paroukatos

STAR determined whether glycaemic control was maintained to a greater degree by an RAS inhibitor/non-DHP CCB than an RAS inhibitor/thiazide diuretic in hypertensive patients with metabolic syndrome. STAR: rationale Metabolic syndrome associated with increased risk of new-onset diabetes and cardiovascular disease. Antihypertensive therapy may be beneficial in reducing...

20 Aug The TRial Of Preventing HYpertension (TROPHY)

Posted at 10:26h in Μελέτες by paroukatos

TROPHY - hypothesis The TRial Of Preventing HYpertension (TROPHY) is an investigator-initiated trial to examine whether early treatment of high-normal blood pressure values (according to JNC VI) with candesartan would prevent or postpone the development of stage 1 hypertension. TROPHY - objectives Primary: to determine whether treatment with...

20 Aug How to design and interpret controlled clinical trials

Posted at 10:25h in Μελέτες by paroukatos

"the dark side of the moon" "How to session" ESH June 2005 Andreas Pittaras MD 10.00 new randomized trials every year >350.000 trials General internists would need to read 20 articles a day all year round to maintain present knowledge Systematic reviews and guidelines reduces this problem Clinical Studies:...

20 Aug Blood Pressure Reduction Is Not the Only Determinantof Outcome

Posted at 10:24h in Μελέτες by paroukatos

Peter S. Sever, FRCP; Neil R. Poulter, FRCP Whether certain classes of antihypertensive drugs confer benefits beyond those associated with lowering blood pressure remains a highly controversial issue. Data from several meta-analyses have been used to support the notion that most, if not all, of the...

20 Aug Is New-Onset Diabetes of Clinical Significance in Treated Hypertensive Patients?—Con

Posted at 10:22h in Μελέτες by paroukatos

Marvin Moser, MD There is little doubt that diabetes is more common in hypertensive than normotensive individuals. There are also some data suggesting that the use of certain antihypertensive agents, i.e., diuretics and more specifically some blockers will increase the occurrence of new onset diabetes (NOD)...

20 Aug Angiotensin II receptor antagonist telmisartan in isolated systolic hypertension (ARAMIS) study: efficacy and safety of telmisartan 20, 40 or 80 mg versus hydrochlorothiazide 12.5 mg or placebo

Posted at 10:22h in Μελέτες by paroukatos

Athanasios J. Manolisa, John L. Reidb, Dick de Zeeuwc, Michael B. Murphyd, Elke Seewaldt-Beckere and Ju¨ rgen Ko¨ sterf on behalf of the ARAMIS Study Group Objective: To identify telmisartan doses that are more effective than placebo and non-inferior to hydrochlorothiazide (HCTZ) 12.5 mg, and are well...

20 Aug More Confusing Messages From the Hypertension Treatment Trials

Posted at 10:21h in Μελέτες by paroukatos

Marvin Moser, MD Editor in Chief Over the past 5 years, numerous hypertension treatment trials have been completed and reported.1-8 A majority of these trials were initiated to distinguish one therapy from another in reducing cardiovascular (CV) events. Some were blinded and appropriately randomized prospective trials;...

Μελέτες